The US FDA has issued an establishment inspection report (EIR) for Shilpa Medicare's generic pharmaceutical manufacturing facility at Jadcherla, Telangana, which was inspected by the health regulator between July 24 and 28, 2017.

The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The US FDA has reviewed the CAPA and found it acceptable.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version